FAQ
This section has been developed to support patients and their families by answering a number of frequently asked questions about:
Overview
Manage your diabetes
Insulin pens and needles
Social support
Overview
Phamaceutical information
Injection devices
Needles
Growth disorders
Programmes & support
Overview
Disease areas
Diabetes care
Exclusively for Health Care Professionals. Stay up to date on Novo Nordisk diabetes products: Victoza®, Levemir®, NovoMix®, NovoRapid® and Devices, and read about current diabetes themes, proven therapeutic options, and knowledge resources and tools for you and your patients.
Overview
Overview
Product info
NovoSeven®
270 µg/kg dose
Room temperature stable
8 mg vial
Haemostasis
Management
Blood coagulation
Educational
Key papers
Treatment guidelines
Services & links
WFH patients'
leaflet
Patient story
Disease areas
Congenital haemophilia
Acquired haemophilia
Factor VII deficiency
Glanzmann's
thrombasthenia
Overview
Overview
Indications
GHD (Growth hormone deficiency)
GHDA (Growth hormone deficiency) in adults
SGA (Small for gestational age)
Turner syndrome
Noonan syndrome
Skeletal dysplasia
Chronic renal disease
Pharmaceutical information
Norditropin®
Injection devices
Norditropin® FlexPro®
Norditropin NordiFlex®
NordiFlex PenMate®
NordiPen® with Norditropin® SimpleXx®
NordiPenMate®
Norditropin® NordiLet®
Needles
NovoFine®
Programmes & support
NordiNet® (outcomes registry)
NordiScience® (HCP support)
NordiCare® (Patient support)
Our partnership with Save the Children
Patient testimonials
Testimonials
Overview
Overview
Our products
Introduction
Activelle®
Eviana®
Novofem®
Estrofem®
Vagifem®
Convenience & compliance
Our history in HRT
About HRT
Introduction
Symptoms & complaints
Duration of treatment
Oestrogen
Progestogen
Continuous combined HRT
Sequential combined HRT
Low-dose HRT
Overview
Haemostasis
Overview
Pharmaceutical information
Needles
Overview
Our products
Log out to deactivate menu
Why only for Health Care Professionals
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Working in
Programmes
Students & Graduates
Events
32 globally oriented graduates needed
Do you have a recent master degree, and do you want a successful career in one of the world's leading pharmaceutical companies? If yes, then the Novo Nordisk Graduate Programme is what you are looking for.
Facts about Novo Nordisk
The Novo Nordisk Way
Management
Publications & Presentations
Changing diabetes®
Changing Possibilities in Haemophilia®
New domicile
Corporate Governance
Novo Nordisk Worldwide
About Novo Nordisk
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries.
Novo Nordisks B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
